KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $43.4 million.

  • Halozyme Therapeutics' Share-based Compensation fell 3.32% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.5 million, marking a year-over-year increase of 11.71%. This contributed to the annual value of $43.4 million for FY2024, which is 18.47% up from last year.
  • As of FY2024, Halozyme Therapeutics' Share-based Compensation stood at $43.4 million, which was up 18.47% from $36.6 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Share-based Compensation ranged from a high of $43.4 million in FY2024 and a low of $17.2 million during FY2020.
  • For the 3-year period, Halozyme Therapeutics' Share-based Compensation averaged around $34.8 million, with its median value being $36.6 million (2023).
  • Its Share-based Compensation has fluctuated over the past 5 years, first tumbled by 50.53% in 2020, then surged by 50.10% in 2023.
  • Yearly analysis of 5 years shows Halozyme Therapeutics' Share-based Compensation stood at $17.2 million in 2020, then rose by 21.02% to $20.8 million in 2021, then rose by 17.18% to $24.4 million in 2022, then skyrocketed by 50.10% to $36.6 million in 2023, then climbed by 18.47% to $43.4 million in 2024.